RSS

MolecularHealth opens U.S. headquarters and clinical lab in The Woodlands

MolecularHealth recently announced the opening of its U.S. headquarters and clinical lab, co-located in The Woodlands, Texas. The new facilities are an important milestone in the company’s path toward the commercialization of its automated genetic diagnostic platform for cancer care in the first quarter of 2014.

MolecularHealth has recently expanded its U.S. executive team and advisory board, anchored by well-known oncology and pathology experts.

“A great deal of work has gone into designing and building a world-class next generation sequencing lab that will enable us to offer testing that is currently unparalleled in the U.S.”

“Our main focus as a company is on the unique and advanced analytics platform we’ve built, which provides oncologists and pathologists extremely valuable and personalized information on their patients’ tumors. But in order to run our analyses, we have developed a lab that can handle everything from preparing samples to conducting whole exome sequencing tests,” added Lloyd Everson, M.D., chief executive officer, U.S. division, for MolecularHealth.

MolecularHealth’s lab, which will run Illumina sequencing equipment, will offer two tests: a targeted gene panel of more than 500 known cancer genes, and whole exome sequencing of the tumor genome. The combined office and lab occupies approximately 7,000 square feet in the Black Forest Technology Park. MolecularHealth expects to fill approximately 40 positions in 2014, including an on-site medical director, genetic technologists and client services representatives.

“A great deal of work has gone into designing and building a world-class next generation sequencing lab that will enable us to offer testing that is currently unparalleled in the U.S.,” said Shelly Gunn, M.D., chief medical officer for MolecularHealth. “This clinical lab was built with the intent of serving cancer patients across the country and making sure that we can guide them and their doctors to the best possible treatment decisions.”

Backed by Dietmar Hopp, co-founder and former chairman and CEO of SAP, MolecularHealth offers an end-to-end service that walks patients and their healthcare providers through the molecular diagnostic process—collecting tumor samples, analyzing the samples, and interpreting the results using a unique analytics platform— all to generate safer and more targeted cancer treatment choices. As part of its offering, MolecularHealth will provide patients, oncologists and pathologists with complete logistical support and help navigating insurance reimbursement for recommended treatments.